公开(公告)号：US20180169232A1

公开(公告)日：2018-06-21

申请号：US15736615

申请日：2016-06-15

Applicant: Glen Ian ANDREWS ,  Shihao CHEN ,  Alessandra DI PIETRO ,  David FONTANA ,  Zelanna GOLDBERG ,  Chia-Yang LIN ,  Hua LONG ,  Marcella MARTIGNONI ,  Dimitry Serge Antotne NUYTEN ,  Aron David THALL ,  Adrian WOOLFSON ,  MERCK PATENT GMBH ,  PFIZER INC.

Inventor： Glen Ian ANDREWS ,  Shihao CHEN ,  Alessandra DI PIETRO ,  David FONTANA ,  Zelanna GOLDBERG ,  Chia-Yang LIN ,  Hua LONG ,  Marcella MARTIGNONI ,  Dimitry Serge Antoine NUYTEN ,  Aron David THALL ,  Adrian WOOLFSON

IPC: A61K39/395 ,  A61K31/4439 ,  C07K16/28 ,  C07K16/24 ,  A61K33/24 ,  A61K31/4184 ,  A61K31/706 ,  A61P35/00

CPC classification number: A61K39/3955 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/706 ,  A61K33/24 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/243 ,  C07K16/2827 ,  C07K16/2878 ,  C07K16/2887 ,  C07K2317/21 ,  C07K2317/76 ,  A61K2300/00

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

公开(公告)号：US20160060344A1

公开(公告)日：2016-03-03

申请号：US14838650

申请日：2015-08-28

Applicant: Rajesh Narwal ,  Marlon C. Rebelatto ,  Keith Steele ,  Paul Robbins ,  Ross Anthony Stewart ,  John A. Blake-Haskins ,  Joyson J. Karakunnel ,  Ramy Ibrahim ,  Aiman Shalabi ,  Alessandra Di Pietro ,  Li Shi ,  Shengyan Hong ,  Paul Stockman ,  Marc Ballas ,  Mohammed M. Dar

Inventor： Rajesh Narwal ,  Marlon C. Rebelatto ,  Keith Steele ,  Paul Robbins ,  Ross Anthony Stewart ,  John A. Blake-Haskins ,  Joyson J. Karakunnel ,  Ramy Ibrahim ,  Aiman Shalabi ,  Alessandra Di Pietro ,  Li Shi ,  Shengyan Hong ,  Paul Stockman ,  Marc Ballas ,  Mohammed M. Dar

IPC: C07K16/28

CPC classification number: C07K16/2827 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2818 ,  C07K2317/21 ,  C07K2317/76

Abstract: The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and tremelimumab in a subject identified as having a PD-L1 negative tumor.

Abstract translation: 本发明的特征在于鉴定为具有PD-L1阴性肿瘤的受试者中具有抗PD-L1抗体和tremeimumab治疗肺癌（例如NSCLC）的方法。